Dravet Syndrome Treatment Market Trends

Growth Drivers

Rising Drug Development – The FDA may collaborate with businesses to develop medications for Dravet syndrome, which is expected to drive market growth. According to recent estimates, the typical R&D expenditure for a new medicine ranges from more than USD 1 billion.
Growing Importance of Genetic Testing- Genetic testing is a straightforward blood test that can reveal sequencing abnormalities in the SCN1A gene that can help in determining whether an individual has Dravet syndrome by analyzing the most prevalent genes linked to epilepsy.

Challenges

High Cost of Treatments - Dravet syndrome is a rare disease that affects a small percentage of people, therefore the medicines for treating this disease are exceedingly expensive, presumably to cover the cost of the research and development. For instance, more than a 20% rise in overall expenses is linked to the absence of treatment for a rare condition.
Complexity Associated With Meeting Regulatory Requirements for the Approval of Rare Disease Treatment
Lack of Awareness among Doctors and Patients Owing to Rarity of Dravet Syndrome

Dravet Syndrome Treatment Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	~11%
Base Year Market Size (2023)	~ USD 0.37 Billion
Forecast Year Market Size (2036)	~ USD 1 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

Increasing child population and the growing research & development are the major factors driving the growth of the market.

The market size of Dravet Syndrome Treatment is anticipated to attain a CAGR of 11% over the forecast period, i.e., 2024 â€“ 2036.

The major players in the market are Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc.

The SGDs segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Dravet Syndrome Treatment Market Trends